Immune Thrombocytopenia clinical trials at UCSF

2 research studies open to eligible people

Immune thrombocytopenia is a condition where your body destroys platelets and causes bleeding. UCSF is recruiting for clinical trials to help people with this condition. One trial is for a drug called rilzabrutinib for patients who have persistent or chronic ITP. Another trial is studying a drug called eltrombopag in children newly diagnosed with ITP, compared to standard treatment.

Showing trials for

  • Eltrombopag vs Standard Front Line Management for Newly Diagnosed Immune Thrombocytopenia (ITP) in Children

    open to eligible people ages 1-18

    This is an investigator initiated, multicenter, open label, randomized phase 3 study for subjects with newly diagnosed ITP from ages 1 to less than 18 years old.

    San Francisco, California and other locations

  • Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP)

    open to eligible people ages 10 years and up

    This is a randomized, double-blind study of rilzabrutinib in patients with persistent or chronic ITP, with an average platelet count of <30,000/μL (and no single platelet count >35,000/μL) on two counts at least 5 days apart in the 14 days before treatment begins. Patients will receive rilzabrutinib or placebo 400mg twice daily. For each patient, the study will last up to 60 weeks from the start of the Screening Period to the End of Study (EOS) visit. This includes Screening (up to 4 weeks) through a 12 to 24-week Blinded Treatment Period followed by a 28-week Open-Label Period. Followed by a 4-week post dose follow-up. For adult participants, the maximum duration of the long-term extension (LTE) period will be 12 months from the date of the last adult participant to enter the LTE. For pediatric participants, the maximum duration of the LTE period will be 12 months from the date of the last pediatric participant to enter the LTE.

    San Francisco, California and other locations

Our lead scientists for Immune Thrombocytopenia research studies include .

Last updated: